| abstract |
The present invention relates to the use of 4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxy-7- (3- (pyrrolidin-1-yl) propoxy) quinazoline or a pharmaceutically acceptable salt thereof and one or more therapeutic an agent selected from (i) another antiangiogenic agent that acts by a mechanism different from that of VEGF receptor tyrosine kinase; (ii) a cytostatic agent; (iii) an antiproliferative / antineoplastic drug and combinations thereof; (iv) biological response modifier; (v) an antibody; for the preparation of a medicament with anti-angiogenic effects and / or blood-permeation-reducing effects and for use in the treatment of cancer in warm-blooded animals such as man. Specifically, it may be colon, breast, prostate, lung or skin cancer. |